NCT02807272View on ClinicalTrials.gov

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Leukemia, Myelomonocytic, Chronic
Interventions
DRUG

Tipifarnib

Oral tablet

Trial Locations (8)

10065

Weill Cornell Medicine, New York

19104

University of Pennsylvania Hospital, Philadelphia

21231

Johns Hopkins University, Baltimore

32224

Mayo Clinic Florida, Jacksonville

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic Rochester, Rochester

85054

Mayo Clinic Arizona, Scottsdale

Sponsors
All Listed Sponsors
lead

Kura Oncology, Inc.

INDUSTRY

NCT02807272 - Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter